ECSP003442A - SYNERGETIC EFFECTS OF AMLODIPINE AND ATORVASTATINE OR METABOLITE OF ATORVASTATINE AS A BASIS FOR COMBINATION THERAPY - Google Patents

SYNERGETIC EFFECTS OF AMLODIPINE AND ATORVASTATINE OR METABOLITE OF ATORVASTATINE AS A BASIS FOR COMBINATION THERAPY

Info

Publication number
ECSP003442A
ECSP003442A ECSP003442A ECSP003442A EC SP003442 A ECSP003442 A EC SP003442A EC SP003442 A ECSP003442 A EC SP003442A EC SP003442 A ECSP003442 A EC SP003442A
Authority
EC
Ecuador
Prior art keywords
amlodipine
combination
atorvastatine
basis
combination therapy
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Preston R Mason
Original Assignee
Preston R Mason
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preston R Mason filed Critical Preston R Mason
Priority to ECSP003442 priority Critical patent/ECSP003442A/en
Publication of ECSP003442A publication Critical patent/ECSP003442A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La combinación de amlodipina sea con atorvastatina o metabolito de atorvastatina muestra un efecto antioxidante sinérgico en la peroxidación de lípido de lipoproteínas humanas de baja densidad y vesiculas de membrana enriquecidas con ácidos grasos polinsaturados. La inhibición del daño oxi-radical por esta combinación de droga se observó a niveles terapéuticos de una manera que no puede ser reproducida por la combinación de amlodipina con otras estatinas o el antioxidante natural, Vitamina E. La base para esta actividad potente se atribuye a las estructuras químicas de estos compuestos y a sus interacciones moleculares con las moléculas de fosdolípidos, como se determina por análisis de difracción de rayos X. Esta terapia de combinación se puede usar para tratar desórdenes cardiovasculares, especialmente, enfermedad coronaria arterial, aumentado la resistencia de las lipoproteínas de baja densidad y las membranbas de célula vascular contra la modificación oxidativa.The combination of amlodipine with either atorvastatin or the atorvastatin metabolite shows a synergistic antioxidant effect on lipid peroxidation of low-density human lipoproteins and membrane vesicles enriched with polyunsaturated fatty acids. Inhibition of oxy-radical damage by this drug combination was observed at therapeutic levels in a way that cannot be reproduced by the combination of amlodipine with other statins or the natural antioxidant, Vitamin E. The basis for this potent activity is attributed to the chemical structures of these compounds and their molecular interactions with phosdolipid molecules, as determined by X-ray diffraction analysis. This combination therapy can be used to treat cardiovascular disorders, especially coronary artery disease, increasing resistance to low-density lipoproteins and vascular cell membranes against oxidative modification.

ECSP003442 2000-04-27 2000-04-27 SYNERGETIC EFFECTS OF AMLODIPINE AND ATORVASTATINE OR METABOLITE OF ATORVASTATINE AS A BASIS FOR COMBINATION THERAPY ECSP003442A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP003442 ECSP003442A (en) 2000-04-27 2000-04-27 SYNERGETIC EFFECTS OF AMLODIPINE AND ATORVASTATINE OR METABOLITE OF ATORVASTATINE AS A BASIS FOR COMBINATION THERAPY

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP003442 ECSP003442A (en) 2000-04-27 2000-04-27 SYNERGETIC EFFECTS OF AMLODIPINE AND ATORVASTATINE OR METABOLITE OF ATORVASTATINE AS A BASIS FOR COMBINATION THERAPY

Publications (1)

Publication Number Publication Date
ECSP003442A true ECSP003442A (en) 2000-08-18

Family

ID=42041070

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP003442 ECSP003442A (en) 2000-04-27 2000-04-27 SYNERGETIC EFFECTS OF AMLODIPINE AND ATORVASTATINE OR METABOLITE OF ATORVASTATINE AS A BASIS FOR COMBINATION THERAPY

Country Status (1)

Country Link
EC (1) ECSP003442A (en)

Similar Documents

Publication Publication Date Title
Petrovic et al. Lipid peroxidation and antioxidant supplementation in neurodegenerative diseases: a review of human studies
Gambini et al. Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans
Cucchiara et al. Use of statins in CNS disorders
BRPI0518398A2 (en) Omega-3 Fatty Acids and Delipidemic Agent for Lipid Therapy
ES2144792T3 (en) USE OF NADPH OXIDASE INHIBITORS FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTION OF ATHEROSCLEROSIS.
CO5611156A2 (en) VASCULAR DISEASE TREATMENT METHODS
Lobato et al. α-Tocopherol administration produces an antidepressant-like effect in predictive animal models of depression
ES2378303T3 (en) Use of polyunsaturated ketones for the treatment of psoriasis
AR022076A1 (en) ANTIOXIDANT COMPOSITION CONSTITUTED BY L-CARNITINE OIL AND ALPHA-LIPOIC ACID TO IMPROVE METABOLIC USE OF GLUCOSE
NO20081067L (en) Treatment with dihydropyndincalcium channel blockers and omega 3 fatty acids, and a combination product thereof
GT200300075BA (en) COMPOUNDS THAT MODULATE PPAR ACTIVITY AND PROCEDURES FOR THEIR PREPARATION (FRACTIONARY PATENT NO. 2 OF THE APPLICATION NO. PI-20030075)
AR007989A1 (en) A METHOD TO REDUCE THE LEVEL OF LIPIDS IN WHEY, CHOLESTEROL AND / OR TRIGLYCERIDES AND TREAT RELATED DISEASES IN A SPECIES OF MAMMALS BY MEANS OF A MICRO-SUCCOLENT TRANSIGERANT PROTEIN (MICROSOMAL). Y
UY28123A1 (en) NEW DERIVATIVES OF AROMATIC FLUOROGLYCHIDS, MEDICINES CONTAINING THESE COMPOUNDS AND THEIR USES.
AR122059A1 (en) USES AND FORMULATIONS OF CANNABINOIDS
AR026621A1 (en) TRANSDERMAL THERAPEUTIC SYSTEMS WITH IMPROVED STABILITY AND A PROCEDURE FOR PREPARATION
UY28209A1 (en) DERIVATIVES OF AMINO ACIDS WITH CYCLLOQUAL, PROCEDURE FOR PREPARATION AND USE AS A MEDICINAL PRODUCT.
Rossoni et al. Wild artichoke prevents the age-associated loss of vasomotor function
AR023391A1 (en) COMPOSITION CONTAINING CARNITINE AND INOSITOL PHOSPHATE, USEFUL AS A DIETARY SUPPLEMENT OR DRUG
Xu et al. Kaempferol enhances endothelium-independent and dependent relaxation in the porcine coronary artery
ES2195939T3 (en) COMPOSITION FOR PREVENTION AND / OR TREATMENT OF CIRCULATORY DISORDERS THAT INCLUDES DERIVATIVES OF L-CARNITINE AND GINKGO BILOBA EXTRACTS.
ECSP003442A (en) SYNERGETIC EFFECTS OF AMLODIPINE AND ATORVASTATINE OR METABOLITE OF ATORVASTATINE AS A BASIS FOR COMBINATION THERAPY
ES2035092T3 (en) LIQUID PRODUCT FOR THE AESTHETIC TREATMENT OF SKIN AND ITS MANUFACTURING PROCEDURE.
UY26118A1 (en) SYNERGIC EFFECTS OF AMLODIPINE AND ATORVASTATINE OR ATORVASTATINE METABOLITE AS A BASIS FOR COMBINED THERAPY.
AR023569A1 (en) SYNERGIC EFFECTS OF AMLODIPIN AND ATORVASTATIN OR METABOLITES OF ATORVASTATIN, AS THE BASE FOR A COMBINED THERAPY
PA8596701A1 (en) DERIVATIVES OF REPLACED AMINO ACIDS WITH CYCLLOQUAL, PROCEDURE FOR PREPARATION AND USE AS MEDICATIONS